Drug Eluting Balloon Market by Product Type (Semi-Compliant Drug Eluting Balloons, Non-Compliant Drug Eluting Balloons), by Application (Coronary Artery Disease, Peripheral Artery Disease), by End-User Industry (Hospitals, Clinics, Ambulatory Surgical Centers), and by Technology (Paclitaxel-based Drug Eluting Balloons, Sirolimus-based Drug Eluting Balloons); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Drug Eluting Balloon Market was valued at USD 593.9 million in 2023 and will surpass USD 1,059.3 million by 2030; growing at a CAGR of 8.6% during 2024 - 2030.

The drug eluting balloon (DEB) market is a rapidly growing segment within the global medical device industry, driven by the increasing prevalence of cardiovascular diseases and the growing preference for minimally invasive procedures. DEBs are used in angioplasty procedures to treat blocked arteries, delivering drugs directly to the treatment site to reduce the risk of restenosis, or the re-narrowing of the artery. These balloons are coated with drugs like paclitaxel or sirolimus, and they are highly effective in ensuring long-term success rates for patients undergoing vascular interventions. The demand for these devices is expected to rise due to technological advancements, the need for efficient, cost-effective treatments, and the expansion of healthcare access in emerging markets.

Semi-Compliant Drug Eluting Balloons Are Largest Owing to Their Versatility

Within the product type segment, semi-compliant drug eluting balloons hold the largest market share. These balloons are designed to accommodate various vessel sizes and are more flexible, which enhances their use in a broader range of applications, especially in coronary artery disease (CAD) and peripheral artery disease (PAD) treatments. Semi-compliant balloons provide a good balance between flexibility and durability, offering superior performance in delivering therapeutic agents such as paclitaxel, a commonly used drug in coronary interventions. Their versatility, ability to expand without exerting excessive force on the artery, and cost-effectiveness contribute to their widespread adoption in the treatment of a variety of arterial conditions, making them a preferred choice for healthcare providers.

The popularity of semi-compliant DEBs is driven by their enhanced performance in coronary interventions, which are one of the most common procedures in hospitals and clinics. Their ability to treat both large and small arteries with precision allows for better patient outcomes and a reduction in post-procedural complications. As the demand for non-invasive treatments continues to grow, the market for semi-compliant DEBs is expected to remain dominant and grow at a steady rate.

Coronary Artery Disease Treatment Is Largest Application Owing to High Incidence Rate

Among the various applications in the drug eluting balloon market, coronary artery disease (CAD) stands out as the largest and most significant. CAD is a leading cause of death globally, with a growing number of people being diagnosed due to lifestyle changes, aging populations, and increasing risk factors such as hypertension and diabetes. Drug-eluting balloons have become a preferred method of treatment for CAD due to their ability to minimize restenosis, which occurs in a significant percentage of patients treated with traditional stents.

Coronary artery disease interventions are often performed in high-volume settings such as hospitals and specialized heart centers. As a result, drug eluting balloons for CAD have a well-established demand, with several companies focusing on enhancing the performance and effectiveness of these devices. The increasing prevalence of CAD and the continuous advancements in DEB technology, such as the introduction of paclitaxel-based coatings, are expected to further boost the demand for coronary drug eluting balloons in the coming years. This growth is also supported by the shift toward more efficient, minimally invasive cardiovascular procedures.

Hospitals Remain the Largest End-User Industry Due to High Treatment Volume

The hospital segment remains the largest end-user industry for drug eluting balloons. Hospitals are the primary setting for most medical procedures involving drug eluting balloons, as they are equipped with the necessary infrastructure and specialized staff for performing complex vascular interventions. With the rising incidence of cardiovascular diseases and peripheral artery diseases, hospitals worldwide are seeing a growing volume of patients requiring angioplasty and stenting procedures. DEBs are a key component of these treatments, especially in high-risk patients, as they offer better outcomes in terms of restenosis prevention compared to bare balloons.

Hospitals benefit from a higher volume of patients and the ability to offer advanced treatment options, driving the demand for drug eluting balloons. This segment is also aided by technological advancements in DEB designs, which provide better safety and efficiency during procedures. Hospitals are anticipated to continue driving the market, particularly as newer treatments and drugs are developed to further enhance the performance of drug eluting balloons.

Paclitaxel-based Drug Eluting Balloons Are Fastest Growing Technology Owing to Their Efficacy

In the technology segment, paclitaxel-based drug eluting balloons are the fastest-growing technology owing to their established effectiveness in reducing restenosis, particularly in coronary artery disease and peripheral artery disease treatments. Paclitaxel, a chemotherapy drug, has proven to significantly lower the chances of artery re-narrowing by inhibiting the growth of smooth muscle cells in the vascular walls. This makes paclitaxel-coated balloons highly sought after for both coronary and peripheral artery interventions.

The growing preference for paclitaxel-based drug-eluting balloons can be attributed to their high success rates in clinical trials and real-world applications. Their usage has expanded significantly in recent years, especially as healthcare providers increasingly focus on providing long-term solutions for patients with chronic conditions. The effectiveness of paclitaxel in treating complex vascular diseases is anticipated to sustain its growth and further propel the demand for paclitaxel-coated drug eluting balloons in the global market.

North America Remains the Largest Region Owing to Advanced Healthcare Infrastructure

North America is the largest region for the drug eluting balloon market, driven by its advanced healthcare infrastructure, high incidence rates of cardiovascular diseases, and the increasing adoption of minimally invasive treatments. The United States is the primary market in this region, with a well-established healthcare system and high demand for innovative medical devices. Hospitals and clinics in North America are increasingly adopting drug eluting balloons to treat coronary artery disease and peripheral artery disease, particularly due to the aging population and the high prevalence of risk factors such as obesity and diabetes.

North America’s dominance is further fueled by the high level of research and development investments in the region, along with stringent regulatory standards that ensure the quality and safety of drug-eluting balloons. The region is expected to maintain its leadership position throughout the forecast period, although Asia-Pacific is emerging as a rapidly growing market due to improving healthcare access and increasing awareness of advanced treatment options.

Competitive Landscape and Leading Companies

The drug eluting balloon market is highly competitive, with several global companies driving innovation and seeking strategic partnerships to expand their product offerings. Medtronic, Boston Scientific, and Abbott Laboratories are the leading players in the market, known for their advanced drug-eluting balloon technologies and strong global distribution networks. These companies have made significant investments in research and development to improve the performance and safety of their products, and they continuously work on introducing new variations, such as paclitaxel and sirolimus-based coatings.

Other notable players in the market include Biotronik, Cook Medical, and Medtronic, who have expanded their portfolios through strategic mergers and acquisitions. The competitive landscape is also marked by frequent collaborations between medical device manufacturers and pharmaceutical companies to enhance the therapeutic efficacy of drug-eluting balloons. As the market grows, these companies will continue to innovate and compete for market share, particularly in emerging regions where healthcare infrastructure is improving rapidly.

Recent Developments:

• Medtronic launched a new paclitaxel-coated drug-eluting balloon, which has received regulatory approval for the treatment of peripheral artery disease, expanding its portfolio in the cardiovascular space.
• Boston Scientific acquired a leading vascular technology firm specializing in drug-eluting balloon products, strengthening its position in the global drug-eluting balloon market.
• Abbott Laboratories received FDA approval for its new sirolimus-coated drug-eluting balloon, enhancing its presence in the coronary artery disease treatment market.
• Terumo Corporation’s innovative non-compliant drug-eluting balloon has received the CE mark, allowing it to expand its presence in European markets for treating peripheral artery disease.
• B. Braun entered a strategic partnership with MicroPort to co-develop and launch a next-generation drug-eluting balloon, which is expected to improve clinical outcomes and expand their global footprint

List of Leading Companies:

• Medtronic
• Boston Scientific
• Abbott Laboratories
• Cook Medical
• B. Braun Melsungen AG
• Terumo Corporation
• Cardinal Health
• Cordis (A Cardinal Health Company)
• STENTYS
• Biotronik
• Smith & Nephew
• MicroPort Scientific Corporation
• Asahi Intecc Co. Ltd.
• Medi-Globe
• MedAlliance

Report Scope: